Literature DB >> 21112165

Anaplasmosis in dogs: the relation of haematological, biochemical and clinical alterations to antibody titre and PCR confirmed infection.

Urska Ravnik1, Natasa Tozon, Katja Strasek Smrdel, Tatjana Avsic Zupanc.   

Abstract

Laboratory and clinical parameters of 149 dogs, exposed to Anaplasma phagocytophilum (A. phagocytophilum), and 19 control dogs were evaluated and compared retrospectively. The aim of our study was to determine statistically significant differences of selected parameters between groups of patients, divided according to the immunofluorescence (IFA) titres, in attempt to improve current diagnostic and treatment criteria. Exposure to A. phagocytophilum was confirmed by IFA and infection by PCR. Based on the results, the dogs were divided into 8 groups (6 groups of seropositive dogs according to the antibody titre, 1 group of PCR positive dogs, and a control group). Selected parameters were compared between groups. Thrombocytopenia was confirmed to be the most prominent haematological change in IFA and/or PCR positive dogs. There were no statistically significant differences in clinical and haematological observations between groups of different IFA titre but clear overall differences between each IFA and PCR positive groups compared to the control group. Our results showed the necessity of introducing additional diagnostic procedures in clinical practice, since antibody titre and haematological parameters are not sufficient to confirm the clinical relevance of exposure to A. phagocytophilum in a particular patient.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21112165     DOI: 10.1016/j.vetmic.2010.10.005

Source DB:  PubMed          Journal:  Vet Microbiol        ISSN: 0378-1135            Impact factor:   3.293


  8 in total

1.  Sensitivity and specificity levels of two rapid assays for antibodies to Anaplasma spp. in dogs.

Authors:  Jiayou Liu; Matthew Eberts; Hannah Bewsey; Thomas P O'Connor; Ramaswamy Chandrashekar; Edward B Breitschwerdt
Journal:  J Vet Diagn Invest       Date:  2017-12-04       Impact factor: 1.279

2.  Comparison of serological and molecular panels for diagnosis of vector-borne diseases in dogs.

Authors:  Ricardo G Maggi; Adam J Birkenheuer; Barbara C Hegarty; Julie M Bradley; Michael G Levy; Edward B Breitschwerdt
Journal:  Parasit Vectors       Date:  2014-03-26       Impact factor: 3.876

3.  Sensitive multiplex PCR assay to differentiate Lyme spirochetes and emerging pathogens Anaplasma phagocytophilum and Babesia microti.

Authors:  Kamfai Chan; Salvatore A E Marras; Nikhat Parveen
Journal:  BMC Microbiol       Date:  2013-12-20       Impact factor: 3.605

4.  A retrospective study of vector-borne disease prevalence in dogs with proteinuria: Southeastern United States.

Authors:  Emily K Purswell; Erin W Lashnits; Edward B Breitschwerdt; Shelly L Vaden
Journal:  J Vet Intern Med       Date:  2020-01-08       Impact factor: 3.333

Review 5.  Epidemiological and Clinicopathological Features of Anaplasma phagocytophilum Infection in Dogs: A Systematic Review.

Authors:  Sarah El Hamiani Khatat; Sylvie Daminet; Luc Duchateau; Latifa Elhachimi; Malika Kachani; Hamid Sahibi
Journal:  Front Vet Sci       Date:  2021-06-23

6.  Effect of owner-controlled acaricidal treatment on tick infestation and immune response to tick-borne pathogens in naturally infested dogs from Eastern Austria.

Authors:  Michael Leschnik; Andrea Feiler; Georg G Duscher; Anja Joachim
Journal:  Parasit Vectors       Date:  2013-03-09       Impact factor: 3.876

7.  Clinicopathological and molecular findings in a case of canine Anaplasma phagocytophilum infection in Northern Italy.

Authors:  Francesco Dondi; Samanta Russo; Chiara Agnoli; Nicola Mengoli; Andrea Balboni; Alberto Alberti; Mara Battilani
Journal:  ScientificWorldJournal       Date:  2014-06-05

8.  Prevalence of Anaplasma phagocytophilum infection in feral cats in Massachusetts.

Authors:  Erin R Galemore; Mary A Labato; Elizabeth O'Neil
Journal:  JFMS Open Rep       Date:  2018-01-23
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.